Advances in stromal cell therapy for management of Alzheimer’s disease
Deposition of misfolded proteins and synaptic failure affects the brain in Alzheimer’s disease (AD). Its progression results in amnesia and cognitive impairment. Absence of treatment is due to excessive loss of neurons in the patients and the delayed effects of drugs. The enhanced pluripotency, prol...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-10-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2022.955401/full |
| _version_ | 1811242851559800832 |
|---|---|
| author | Rashi Srivastava Aidong Li Tirtharaj Datta Niraj Kumar Jha Salehikram Talukder Saurabh Kumar Jha Saurabh Kumar Jha Saurabh Kumar Jha Zhe-Sheng Chen Zhe-Sheng Chen |
| author_facet | Rashi Srivastava Aidong Li Tirtharaj Datta Niraj Kumar Jha Salehikram Talukder Saurabh Kumar Jha Saurabh Kumar Jha Saurabh Kumar Jha Zhe-Sheng Chen Zhe-Sheng Chen |
| author_sort | Rashi Srivastava |
| collection | DOAJ |
| description | Deposition of misfolded proteins and synaptic failure affects the brain in Alzheimer’s disease (AD). Its progression results in amnesia and cognitive impairment. Absence of treatment is due to excessive loss of neurons in the patients and the delayed effects of drugs. The enhanced pluripotency, proliferation, differentiation, and recombination characteristics of stromal cells into nerve cells and glial cells present them as a potential treatment for AD. Successful evidence of action in animal models along with positive results in preclinical studies further encourage its utilization for AD treatment. With regard to humans, cell replacement therapy involving mesenchymal stromal cells, induced-pluripotent stromal cells, human embryonic stromal cells, and neural stems show promising results in clinical trials. However, further research is required prior to its use as stromal cell therapy in AD related disorders. The current review deals with the mechanism of development of anomalies such as Alzheimer’s and the prospective applications of stromal cells for treatment. |
| first_indexed | 2024-04-12T13:57:11Z |
| format | Article |
| id | doaj.art-a2d7ec0784be44479d0f5743816e1654 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-04-12T13:57:11Z |
| publishDate | 2022-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-a2d7ec0784be44479d0f5743816e16542022-12-22T03:30:20ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122022-10-011310.3389/fphar.2022.955401955401Advances in stromal cell therapy for management of Alzheimer’s diseaseRashi Srivastava0Aidong Li1Tirtharaj Datta2Niraj Kumar Jha3Salehikram Talukder4Saurabh Kumar Jha5Saurabh Kumar Jha6Saurabh Kumar Jha7Zhe-Sheng Chen8Zhe-Sheng Chen9Chemical and Biochemical Engineering, Indian Institute of Technology, Patna, IndiaDepartment of Rehabilitation, The Second People’s Hospital of Shenzhen, Shenzhen, ChinaDepartment of Biotechnology, School of Engineering and Technology, Sharda University, Greater Noida, IndiaDepartment of Biotechnology, School of Engineering and Technology, Sharda University, Greater Noida, IndiaInstitute for Biotechnology, St. John’s University, New York City, NY, United StatesDepartment of Biotechnology, School of Engineering and Technology, Sharda University, Greater Noida, IndiaDepartment of Biotechnology, School of Applied and Life Sciences, Uttaranchal University, Dehradun, IndiaDepartment of Biotechnology Engineering and Food Technology, Chandigarh University, Mohali, IndiaInstitute for Biotechnology, St. John’s University, New York City, NY, United StatesDepartment of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John’s University, New York City, NY, United StatesDeposition of misfolded proteins and synaptic failure affects the brain in Alzheimer’s disease (AD). Its progression results in amnesia and cognitive impairment. Absence of treatment is due to excessive loss of neurons in the patients and the delayed effects of drugs. The enhanced pluripotency, proliferation, differentiation, and recombination characteristics of stromal cells into nerve cells and glial cells present them as a potential treatment for AD. Successful evidence of action in animal models along with positive results in preclinical studies further encourage its utilization for AD treatment. With regard to humans, cell replacement therapy involving mesenchymal stromal cells, induced-pluripotent stromal cells, human embryonic stromal cells, and neural stems show promising results in clinical trials. However, further research is required prior to its use as stromal cell therapy in AD related disorders. The current review deals with the mechanism of development of anomalies such as Alzheimer’s and the prospective applications of stromal cells for treatment.https://www.frontiersin.org/articles/10.3389/fphar.2022.955401/fullcellular therapymesenchymal stromal cellAlzheimer’sclinical trialmanagement |
| spellingShingle | Rashi Srivastava Aidong Li Tirtharaj Datta Niraj Kumar Jha Salehikram Talukder Saurabh Kumar Jha Saurabh Kumar Jha Saurabh Kumar Jha Zhe-Sheng Chen Zhe-Sheng Chen Advances in stromal cell therapy for management of Alzheimer’s disease Frontiers in Pharmacology cellular therapy mesenchymal stromal cell Alzheimer’s clinical trial management |
| title | Advances in stromal cell therapy for management of Alzheimer’s disease |
| title_full | Advances in stromal cell therapy for management of Alzheimer’s disease |
| title_fullStr | Advances in stromal cell therapy for management of Alzheimer’s disease |
| title_full_unstemmed | Advances in stromal cell therapy for management of Alzheimer’s disease |
| title_short | Advances in stromal cell therapy for management of Alzheimer’s disease |
| title_sort | advances in stromal cell therapy for management of alzheimer s disease |
| topic | cellular therapy mesenchymal stromal cell Alzheimer’s clinical trial management |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2022.955401/full |
| work_keys_str_mv | AT rashisrivastava advancesinstromalcelltherapyformanagementofalzheimersdisease AT aidongli advancesinstromalcelltherapyformanagementofalzheimersdisease AT tirtharajdatta advancesinstromalcelltherapyformanagementofalzheimersdisease AT nirajkumarjha advancesinstromalcelltherapyformanagementofalzheimersdisease AT salehikramtalukder advancesinstromalcelltherapyformanagementofalzheimersdisease AT saurabhkumarjha advancesinstromalcelltherapyformanagementofalzheimersdisease AT saurabhkumarjha advancesinstromalcelltherapyformanagementofalzheimersdisease AT saurabhkumarjha advancesinstromalcelltherapyformanagementofalzheimersdisease AT zheshengchen advancesinstromalcelltherapyformanagementofalzheimersdisease AT zheshengchen advancesinstromalcelltherapyformanagementofalzheimersdisease |